Stock analysts at Northland Securities assumed coverage on shares of Motif (NASDAQ:MTFB) in a note issued to investors on Monday. The brokerage set an “outperform” rating on the stock.
A number of other research firms have also recently commented on MTFB. ValuEngine upgraded Motif from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. WBB Securities assumed coverage on Motif in a research report on Friday, December 29th. They set a “sell” rating and a $7.00 target price on the stock. Seaport Global Securities reiterated a “buy” rating on shares of Motif in a research report on Friday, December 22nd. Finally, Gabelli reissued a “hold” rating on shares of Motif in a report on Thursday, March 29th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $21.33.
MTFB opened at $9.95 on Monday. The company has a debt-to-equity ratio of -1.58, a quick ratio of 0.96 and a current ratio of 0.96. Motif has a one year low of $6.84 and a one year high of $13.75. The stock has a market cap of $1,952.31, a PE ratio of -52.37 and a beta of 0.21.
TRADEMARK VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/18/northland-securities-initiates-coverage-on-motif-mtfb.html.
Motif Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.
Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.